300 related articles for article (PubMed ID: 23483513)
21. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability.
Konstas AG; Labbé A; Katsanos A; Meier-Gibbons F; Irkec M; Boboridis KG; Holló G; García-Feijoo J; Dutton GN; Baudouin C
Expert Opin Drug Saf; 2021 Apr; 20(4):453-466. PubMed ID: 33478284
[No Abstract] [Full Text] [Related]
22. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
Goldberg I; Graham SL; Crowston JG; d'Mellow G;
Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
[TBL] [Abstract][Full Text] [Related]
23. Risk factors to develop ocular surface disease
in treated glaucoma or ocular hypertension patients.
Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
[TBL] [Abstract][Full Text] [Related]
24. [Preservatives in ophthalmology].
Messmer EM
Ophthalmologe; 2012 Nov; 109(11):1064-70. PubMed ID: 23179809
[TBL] [Abstract][Full Text] [Related]
25. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
Baudouin C
Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
[TBL] [Abstract][Full Text] [Related]
26. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial.
Stalmans I; Oddone F; Cordeiro MF; Hommer A; Montesano G; Ribeiro L; Sunaric-Mégevand G; Rossetti L
Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1151-8. PubMed ID: 26907933
[TBL] [Abstract][Full Text] [Related]
27. [Modification of tear film break-up time by beta blocker eyedrops without preservatives].
Marquardt R; Schubert T
Klin Monbl Augenheilkd; 1991 Aug; 199(2):75-8. PubMed ID: 1960936
[TBL] [Abstract][Full Text] [Related]
28. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review.
Yee RW
Curr Opin Ophthalmol; 2007 Mar; 18(2):134-9. PubMed ID: 17301615
[TBL] [Abstract][Full Text] [Related]
29. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
30. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
31. [Antiglaucoma drops--with or without preservatives].
Zemba M
Oftalmologia; 2009; 53(2):26-30. PubMed ID: 19697836
[TBL] [Abstract][Full Text] [Related]
32. Preservatives in glaucoma medication.
Steven DW; Alaghband P; Lim KS
Br J Ophthalmol; 2018 Nov; 102(11):1497-1503. PubMed ID: 29973365
[TBL] [Abstract][Full Text] [Related]
33. Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016.
Chamard C; Larrieu S; Baudouin C; Bron A; Villain M; Daien V
Acta Ophthalmol; 2020 Nov; 98(7):e876-e881. PubMed ID: 32232968
[TBL] [Abstract][Full Text] [Related]
34. Unilateral drug-induced ocular pseudopemphigoid.
Gibran SK
Eye (Lond); 2004 Dec; 18(12):1270. PubMed ID: 15044940
[No Abstract] [Full Text] [Related]
35. [Effects of preservatives in anti-glaucoma agents on the ocular surface].
Potop V
Oftalmologia; 2009; 53(2):92-6. PubMed ID: 19697847
[TBL] [Abstract][Full Text] [Related]
36. [The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)].
Dorofeev DA; Tur EV; Vizgalova LO; Tryapitsin ID; Ciganov AZ
Vestn Oftalmol; 2019; 135(6):52-59. PubMed ID: 32015308
[TBL] [Abstract][Full Text] [Related]
37. Prescription trends for preservative free glaucoma medication in a public health system.
Pérez-García P; Burgos-Blasco B; Morales-Fernández L; Fernández-Ruiz-Morón A; Gómez-Calleja V; Oribio-Quinto C; Collado-Vincueria I; Garcia-Feijoo J; Martinez-de-la-Casa JM
Eur J Ophthalmol; 2024 Jan; 34(1):193-203. PubMed ID: 37070183
[TBL] [Abstract][Full Text] [Related]
38. Improvement of objective ocular redness measured with Keratograph 5M in glaucoma patients after instilling brimonidine drops.
Montolío-Marzo E; Fernández-Narros R; Morales-Fernández L; García-Bella J; Sáenz-Francés F; García-Feijoo J; Martínez-de-la-Casa JM
Eur J Ophthalmol; 2024 Mar; 34(2):480-486. PubMed ID: 37661653
[TBL] [Abstract][Full Text] [Related]
39. Intraocular light scatter in patients on topical intraocular pressure-lowering medication.
Pérez-Bartolomé F; Martínez de la Casa JM; Arriola-Villalobos P; Fernández-Pérez C; García-Feijoó J
Eur J Ophthalmol; 2018 Nov; 28(6):652-661. PubMed ID: 29631441
[TBL] [Abstract][Full Text] [Related]
40. Ocular Surface Disease in Glaucoma Patients.
Scelfo C; ElSheikh RH; Shamim MM; Abbasian J; Ghaffarieh A; Elhusseiny AM
Curr Eye Res; 2023 Mar; 48(3):219-230. PubMed ID: 35179417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
